Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLC

Omega Fund Management LLC lessened its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 49.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,184,636 shares of the company's stock after selling 1,171,268 shares during the period. Lexeo Therapeutics comprises approximately 6.5% of Omega Fund Management LLC's holdings, making the stock its 4th biggest holding. Omega Fund Management LLC owned about 3.58% of Lexeo Therapeutics worth $7,795,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LXEO. Janus Henderson Group PLC increased its position in Lexeo Therapeutics by 15.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock worth $28,508,000 after buying an additional 576,059 shares during the last quarter. Altium Capital Management LLC purchased a new position in Lexeo Therapeutics in the fourth quarter worth about $2,665,000. DAFNA Capital Management LLC boosted its stake in shares of Lexeo Therapeutics by 56.9% in the fourth quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock worth $2,586,000 after acquiring an additional 142,500 shares during the period. Privium Fund Management B.V. bought a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $909,000. Finally, ADAR1 Capital Management LLC boosted its position in Lexeo Therapeutics by 196.5% in the 4th quarter. ADAR1 Capital Management LLC now owns 169,505 shares of the company's stock valued at $1,115,000 after buying an additional 112,339 shares during the period. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Trading Down 2.2%

NASDAQ LXEO opened at $2.63 on Tuesday. The firm has a market cap of $87.31 million, a PE ratio of -0.83 and a beta of 1.27. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $3.06 and a 200-day moving average of $5.09. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). As a group, sell-side analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on LXEO shares. Royal Bank of Canada reduced their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. HC Wainwright restated a "buy" rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Chardan Capital reduced their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a report on Tuesday, April 8th. Finally, Leerink Partners dropped their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and a consensus target price of $22.20.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.